Rare Disease is expected to approach about 60% of 2026 revenue, with Cortrophin positioned as the main multi-year growth driver.
Gout expansion became fully operational by end-June; the Rare Disease sales force expanded about 50% to roughly 180 representatives.
2026 guidance and revenue outlook
ANI Pharmaceuticals reaffirmed 2026 guidance for total net revenue of $1.08 billion-$1.14 billion; adjusted non-GAAP EBITDA of $285 million-$300 million.
Cortrophin Gel net revenue outlook was reset to $520 million-$540 million from $540 million-$575 million; ILUVIEN guidance was kept at $78 million-$83 million.
Adjusted non-GAAP diluted EPS forecast was maintained at $9.19-$9.69; adjusted non-GAAP gross margin is expected at 59.9%-60.9%.
ANIP•
